Page 2 - Mark Mintun News Today

WASHINGTON—Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening—by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after the recently…

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study. If U.S. regulators approve, the drug would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brai...

Early detection, regular monitoring are key, experts say, as new Alzheimer’s treatment options emerge

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved…

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months — but comes with safety risks.

Eli Lilly and Company (NYSE: LLY) presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease (AD). The data were shared at the 2023 Alzheimer's Association International Conference ...

WASHINGTON (AP) — Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

New research shows another experimental Alzheimers drug can modestly slow patients inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.s donanemab declined about four to seven months more